Achieve Life Sciences, Inc.

NasdaqCM:ACHV Stock Report

Market Cap: US$481.5m

Achieve Life Sciences Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Andrew Goldberg

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure1.3yrs

Recent management updates

Recent updates

New Narrative • Apr 02

Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains

Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on bringing cytisinicline, a nicotine dependence treatment, to market for smoking and vaping cessation. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 19

Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity

Catalysts About Achieve Life Sciences Achieve Life Sciences is a clinical stage biopharmaceutical company focused on developing cytisinicline as a treatment for nicotine dependence in smokers and vapers. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05

FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story

Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence in smokers and people who vape. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Feb 04

Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

Summary Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV’s market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion. I rate ACHV a strong buy, citing favorable approval odds and blockbuster potential, but note dilution and supply chain risks. Read the full article on Seeking Alpha
Analysis Article • Feb 15

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jul 01

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Summary Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of cytisinicline in the 1st half of 2025. The global smoking cessation product market is estimated to reach $69.8 billion by the end of 2034. Potential label expansion opportunity exists of using cytisinicline for e-cigarettes or vaping cessation patients; End-of-phase 2 meeting expected in 2024. Read the full article on Seeking Alpha

CEO

Andrew Goldberg (43 yo)

less than a year
Tenure

Dr. Andrew D. Goldberg, M.D. is Chief Executive Officer, President and Director of Achieve Life Sciences, Inc. from April 18, 2026. Dr. Goldberg was a Partner of Innovation at Vivo Capital, LLC. He was a P...

Leadership Team

NamePositionTenureCompensationOwnership
Erik Atkisson
Chief Legal Officerless than a yearUS$1.37mno data
Jaime Xinos
Chief Commercial Officer9.3yrsUS$944.60k0.072%
$ 349.1k
Andrew Goldberg
CEO, President & Directorless than a yearno datano data
Mark Oki
Chief Financial Officer1.4yrsUS$1.41m0.12%
$ 600.1k
Craig Donnelly
Chief Operations Officerless than a yearno data0.051%
$ 245.6k
Jerry Wan
VP of Finance & Principal Accounting Officerno datano data0.032%
$ 153.3k
Mark Rubinstein
Chief Medical Officer1.6yrsno data0.039%
$ 185.7k
Mark Zappia
Senior Vice President of Commercialno datano datano data
Nicole Jones
Vice President of Strategic Communications & Stakeholder Relationsno datano datano data
0.7yrs
Average Tenure
48yo
Average Age

Experienced Management: ACHV's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Andrew Goldberg
CEO, President & Directorless than a yearno datano data
Richard A. Stewart
Director9.3yrsUS$1.37m0.22%
$ 1.1m
Stuart Duty
Independent Director3.2yrsUS$140.43k0%
$ 0
Aaron Royston
Independent Directorless than a yearno datano data
Lucian Iancovici
Independent Chairmanless than a yearno datano data
Kristen Slaoui
Independent Director1.3yrsUS$259.93k0%
$ 0
Thomas Sellig
Independent Director3.2yrsUS$139.43k0%
$ 0
Bridget Martell
Independent Director5.2yrsUS$135.68k0%
$ 0
Nancy Phelan
Independent Director1.3yrsUS$241.26k0%
$ 0
David Smith
no datano datano data
Christopher Martin
Directorno datano datano data
Neil Clendeninn
no datano datano data
1.3yrs
Average Tenure
55yo
Average Age

Experienced Board: ACHV's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 19:34
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Achieve Life Sciences, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanCanaccord Genuity
null nullCG Capital
Gary NachmanCGS International